Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
September 30, 2014, 04:48:10 PM

Login with username, password and session length


Members
  • Total Members: 23588
  • Latest: obie1
Stats
  • Total Posts: 640591
  • Total Topics: 48656
  • Online Today: 240
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: CROI: Kivexa and Truvada have similar efficacy and safety  (Read 1592 times)

0 Members and 1 Guest are viewing this topic.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
CROI: Kivexa and Truvada have similar efficacy and safety
« on: February 18, 2008, 01:16:04 AM »
February 14, 2008
http://www.aidsmap.com/en/news/B13012A7-66F5-470C-84E5-24142192FCC3.asp

Abacavir/3TC is comparable to tenofovir/FTC in virologic efficacy when combined with lopinavir/ritonavir through 48 weeks.

After 48 weeks of treatment, equal numbers of patients treated with Kivexa (68%) and Truvada (67%) had a viral load below 50 copies/ml. This demonstrated the virologic non-inferiority of Kivexa to Truvada.

When the investigators looked at viral suppression in patients with high baseline viral loads - above 100,000 copies/ml, they once again found that the two products had equal efficacy, with 63% of Kivexa-treated patients with a viral load above this level having an undetectable viral load at week 48 compared to 65% of those taking Truvada.

Comparable proportions of patients taking each product (Kivexa, 12%; Truvada, 11%) experienced virologic failure. This failure was more likely to involve the NRTI-associated M184V mutation in the Truvada-treated patients than in the Kivexa-treated patients.

Median CD4 cell counts after 48 weeks of treatment were 429 cells/mm3 in the Kivexa-treated patients and 370 cells/mm3 in the patients taking Truvada.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.